Tex. Health & Safety Code § 1003.060 · Subchapter B. PROVISION OF INVESTIGATIONAL STEM CELL TREATMENTS TO PATIENTS WITH CERTAIN SEVERE CHRONIC DISEASES OR TERMINAL ILLNESSES
CONSTRUCTION OF SUBCHAPTER.
Text — Current through the 89th 2nd Called Legislative Session, 2025
This subchapter may not be construed to:
(1) prohibit a physician from using adult stem cells for their intended homologous use if the stem cells are:
(A) produced by a manufacturer registered by the United States Food and Drug Administration; and
(B) commercially available; or
(2) require an institutional review board to oversee treatment using adult stem cells registered by the United States Food and Drug Administration for their intended homologous use.
Notes and commentary — not statutory text
History
Added by Acts 2019, 86th Leg., R.S., Ch. 1158 (H.B. 3148), Sec. 5, eff. September 1, 2019.
Source of truth
- Edition
- Current through the 89th 2nd Called Legislative Session, 2025
- Official file
- https://statutes.capitol.texas.gov/Docs/HS/htm/HS.1003.htm
- Text hash
- sha256 7d2f313c652f3978ff362eaa2d153b1890ddd9c421efad0df22910e36bfa0942
- Composed by
- compose_tx.py 2026-10-05: the Legislative Council's chapter files read in document order; verify_tx.py's independent reading (lxml DOM walk) agrees character for character
Procedural information only. Not legal advice and not a substitute for the advice of an attorney. Confirm the current text with the official publisher before relying on it.